Global investment company Platinum Equity submitted a binding offer to the Johnson & Johnson Family of Companies to buy LifeScan Inc. for $2.1 billion.
AMO Pharma reported that patients treated with its Phase II neuromuscular treatment for onset myotonic dystrophy type 1 experienced clinical benefits such as an improvement in cognitive function and an increased ability to perform daily tasks.
Shares of Adaptimmune Ltd. surged after the company reported three partial responses in three of the four myxoid/round cell liposarcoma patients the company dosed with its NY-ESO SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells.
Tetra Discovery Partners announced that the U.S. Food and Drug Administration gave the Grand Rapids, Michigan-based company’s Investigational New Drug application for BPN14770 the go-ahead for Fragile X Syndrome and potentially other autism spectrum disorders, as well as Alzheimer’s disease.
With two major prescription drug supply deals announced within a four-month period, the landscape of pharmacy benefits management is changing dramatically.
Two years after securing $46 million in financing from the likes of Celgene and Novartis, South San Francisco-based Ideaya Biosciences completed another successful fundraising round with support from GV (formerly Google Ventures) and Roche Venture Fund.
Ionis Pharmaceuticals signed a worldwide license deal with Akcea Therapeutics for the experimental rare disease drugs inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion.
A U.S. Food and Drug Administration decision to slap a clinical hold on Solid Biosciences’s experimental gene therapy treatment for Duchenne muscular dystrophy sent share prices plunging.
Elizabeth Holmes, the founder of embattled biotech Theranos Inc., and former company president Sunny Balwani were charged with massive fraud by the U.S. Securities and Exchange Commission.
Foghorn Therapeutics, based in Cambridge, Massachusetts, officially launched with a $50 million investment from Flagship Pioneering and associated investors.
Auris Medical AG announced that the Swiss-based company’s Phase III tinnitus trial for Keyzilen failed to meet endpoints.
Five months after the company’s lead drug began Phase I testing, San Diego-based Crinetics Pharmaceuticals Inc. secured $63.5 million in Series B financing.
AbbVie and Neurocrine Biosciences announced that the Phase III ELARIS UF-II clinical trial of elagolix for uterine fibroids met its primary endpoint.
Tech companies, such as Google, Apple, Facebook, Amazon and others, have been making significant forays into the life sciences. Although many have praised the ambitions, innovation and deep pockets these companies bring to the industry, a new report by global consulting and advisory company EY suggests that life science companies are in danger of falling behind their tech brethren.
The U.S. Food and Drug Administration granted Cambridge, Mass.-based Proteostasis Therapeutics‘ investigational cystic fibrosis add-on therapy Breakthrough Therapy Designation.
The U.S. FDA accepted Merck & Company’s supplemental Biologics License Application and granted Priority Review for Keytruda (pembrolizumab) in advanced cervical cancer.
Shares of Advaxis Inc. were down more than 21 percent in after the company announced that the U.S. FDA halted a Phase I/II trial that uses an AstraZeneca Pharmaceuticals LP drug following the death of a patient.
Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.
Realm Therapeutics Inc.’s PR013 failed to show efficacy in its Phase II trial for allergic conjunctivitis.